{
    "doi": "https://doi.org/10.1182/blood.V114.22.1259.1259",
    "article_title": "Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative. ",
    "article_date": "November 20, 2009",
    "session_type": "CLL - BIOLOGY AND PATHOPHYSIOLOGY, EXCLUDING THERAPY POSTER I",
    "abstract_text": "Abstract 1259 Poster Board I-282 We describe the clinical-biological features of 63 cases of variant B chronic lymphocytic leukemia (v-B-CLL), characterized by a mantle cell lymphoma-like immunophenotype, atypical cytomorphology in absence of t(11;14)(q13;q32) in FISH analysis. A historical series of 130 B-CLL was used as comparison. The v-B-CLL were significantly different from the B-CLL in terms of the following clinico-hematological variables: age <70 yrs (p <.001), lymphocytosis <20 \u00d7 10 9 / (p <.001), lymphocyte doubling time < 12 months (p = .02), high serum \u03b22-microglobulin levels (p <.001), and splenomegaly (p = .002). Considering immunophenotipic features, CD38 and CD49d expression were significantly more expressed in v-B-CLL than B-CLL (p <.001); whereas, no statistical difference was observed for ZAP-70 reactivity. Considering the IgV H mutation status, there were more patients mutated in the v-B-CLL group than in the B-CLL group (p = .001). Other significant differences were found about the frequency of the recurrent chromosome alterations, evaluated by means of FISH analysis: trisomy 12 was more frequent in v-B-CLL ( p<.001), while del13q14, considered as a single alteration, was more frequent in B-CLL (p=.008). Gene expression profiling of a panel of 9 v-B-CLL compared with 60 B-CLL samples indicated that the variant group is characterized by a specific molecular pattern of gene expression. In particular we observed the upregulation of tumor protein D52 ( TPD52) , and that of 6 genes ( AFF1, GMPS, PICALM, JUN, REL, RAC2 ) known to be protooncogenes. Furthermore, we found that upregulated genes with apoptosis related functions ( IL-7, HSP90B1, NOTCH2, BECN1, ANXA4, MCL1 ) are all negative regulators of apoptosis. Microarray analysis revealed that various genes ( TRIM38, EEF1D, CASP1, MALT1, RHOH0 ) involved in the I-kB kinase/NF-kB cascade of the canonical NF-kB signaling pathway, are furtherly upregulated in v-B-CLL. Furthermore, among the genes found differentially expressed in SAM analysis, we observed also the upregulation of CD1c (according to the surface expression of this antigen), OSBPL3 and ITGA4. After a median follow-up of 55 months (range 4-196) and 60 months (range 6-180), 25/42 (59%) v-CLL and 55/93 (59 %) CLL pts were treated. TTT was significant different between 2 groups when the IgV H mutational status was considered (p= .006). Median OS of v-CLL subset was 112 months vs 171 months of CLL subset. When the IgV H mutational status was considered, mutated cases showed a worse OS even if a statistical difference was not observed (p= 0.062). In conclusion, our study identifies, on the basis of a defined CFM-FISH diagnostic approach, a variant form of B-CLL that shows peculiar biological and clinical features that should be considered in the future clinical and prognostic studies. The inclusion of this form in B-CLL study could alter the interpretation of results, especially related to biological markers. Disclosures No relevant conflicts of interest to declare.",
    "topics": [
        "chronic b-cell leukemias",
        "chronic lymphocytic leukemia",
        "immunophenotyping",
        "lymphoma",
        "nf-kappa b",
        "antigens",
        "apoptosis regulatory proteins",
        "atypical",
        "biological markers",
        "brachial plexus neuritis"
    ],
    "author_names": [
        "Andrea Ferrario, MD",
        "Lilla Cro, PhD",
        "Nadia Zucal",
        "Marta Lionetti, PhD",
        "Francesco Bertoni, MD",
        "Lucia Nobili, PhD",
        "Sonia Fabris, PhD",
        "Katia Todoerti, PhD",
        "Fortunato Morabito, MD",
        "Giovanna Cutrona, PhD",
        "Agostino Cortelezzi, MD",
        "Andrea Guffanti, MD",
        "Maria Cecilia Goldaniga, MD",
        "Stefano Luminari, MD",
        "Luigi Marcheselli, PhD",
        "Manlio Ferrarini, MD",
        "Antonino Neri, MD",
        "Giorgio Lambertenghi Deliliers, MD",
        "Luca Baldini, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Andrea Ferrario, MD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Lilla Cro, PhD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nadia Zucal",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marta Lionetti, PhD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Bertoni, MD",
            "author_affiliations": [
                "Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lucia Nobili, PhD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sonia Fabris, PhD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Katia Todoerti, PhD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fortunato Morabito, MD",
            "author_affiliations": [
                "U.O.C. di Ematologia, Azienda Ospedaliera di Cosenza, Italy, Cosenza, Italy, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giovanna Cutrona, PhD",
            "author_affiliations": [
                "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, Genova, Italy, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Agostino Cortelezzi, MD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Guffanti, MD",
            "author_affiliations": [
                "Divisione Medicina I, Ospedale Fatebenefratelli e Oftalmico, Milano, Milano, Italy, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Cecilia Goldaniga, MD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefano Luminari, MD",
            "author_affiliations": [
                "Dipartimento di Oncologia ed Ematologia, Universita' di Modena e Reggio Emilia, Modena, Italy, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luigi Marcheselli, PhD",
            "author_affiliations": [
                "Dipartimento di Oncologia ed Ematologia, Universita' di Modena e Reggio Emilia, Modena, Italy, "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Manlio Ferrarini, MD",
            "author_affiliations": [
                "Medical Oncology Center - Onclogy, Biology and Genetic Department, IST Genova - University of Genova, Genova, Italy"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonino Neri, MD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giorgio Lambertenghi Deliliers, MD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luca Baldini, MD",
            "author_affiliations": [
                "UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Universita\u0300 degli Studi di Milano, Milano, Italy, "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-14T07:03:42",
    "is_scraped": "1"
}